Multi-organ failure (MOF) is one of the most difficult problems in critically ill patients. Despite significant progress in the treatment of MOF, the mortality rate remains high. About 500,000 patients die every year in Western Europe and the USA in intensive care units (ICUs) because of MOF. If two organs are failing at the same time, the mortality risk increases to over 50%. If the liver, lung, and kidney fail at the same time, the mortality rate is over 75%.(1) In these cases physicians on the ICU are confronted with the challenge of treating several failing organs with independent organ support devices. An integrated therapy solution did not exist so far. The simultaneous application of specific single therapy systems (for liver, lung, and kidney) is difficult to manage since the systems are independent and do not communicate with each other. An integrated therapy system for multi-organ support benefits both the patients and the medical staff applying it.
Solving many problems in a single device
ADVITOS offers a solution to multi-organ failure in intensive care: the world’s first dialysis treatment for acid-base balance including four organ support therapies. The ADVOS therapy improves survival of ICU patients by simultaneously supporting all three main detoxification organs (the liver, the lungs, and the kidneys) and offering blood pH management by acid-base-balance correction and CO2 removal in one single device. With the assistance of the ADVOS multi it is possible to bridge life and so significantly increase the survival rate of patients in intensive care. A significant reduction in the expected mortality was shown in an ADVOS registry study underlining the therapeutic success of the ADVOS therapy.(2)
The ADVOS Technology - How it works
The ADVOS procedure is an innovative blood purification technology and represents an evolution from conventional dialysis machines. Protein-enriched dialysate is used instead of regular dialysate allowing the selective removal of specific toxins with targeted settings of the dialysis fluid pH. Within the device, the dialysate is permanently reprocessed and cleared of toxins to maintain a consistently high detoxification performance.
This unique principle physiologically balances the patient's blood pH in the same way the organs do. As soon as the patient is connected to the ADVOS multi the blood contaminated with toxins is passed through the dialysers. The dialysate absorbs both water-soluble and protein-bound toxins and is then purified from those toxins within an additional circuit where the toxins are separated and disposed of as filtrate.
Improving access to visionary technology
ADVITOS has shown that breakthroughs are still possible in a highly developed, complex, regulated and technically challenging MedTech world. The company's vision is to establish effective organ support and acidosis therapies as standard of care for millions of intensive care patients worldwide. ADVITOS is continuously improving its products to further simplify complex treatments, provide patients with individualised multi-organ support and improve patient survival.
(1) Vincent et al. (1998). Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentre, prospective study.
(2) Fuhrmann V, et al. Critical Care. 2023; 27(S1): P310
